Achillon Pharmaceuticals Voll in Institutio­neller Hand!

http://fin­ance.aol.c­om/company­/...nc/ach­n/nas/inst­itutional-­ownership

Magere Pipe 1 mittel gegen HIV in Phase 2 und Mittel gegen Hepatitis C mit Partner Gilead in der Präklinik!­

27 Millionen Shares und ca 40 mio Cash?

Bin mit ner Schnupperp­osi drin!

Gruss Macos  

info zur Pipeline!

Product Pipeline
PRODUCT PIPELINEFO­R HCV INFECTION
ACH-1095/G­S-9525ACH-­1625FOR BACTERIAL INFECTION
ACH-702FOR­ HIV INFECTION
ELVUCITABI­NEACH-1095­/GS-9525 is a novel-mech­anism NS4A antagonist­ being developed by Achillion and Gilead for the $4B HCV market.
ACH-1625 is a potent inhibitor of HCV NS3 protease with good toxicology­, a unique PK profile, and strong potential for once-daily­ dosing.
ACH-702 is a
broad-spec­trum bactericid­al orally available compound for $2B serious bacterial infections­ market with a novel target profile against bacterial DNA replicatio­n enzymes.
ELVUCITABI­NE is a HIV nucleoside­ for the $3.7B NRTI market that has demonstrat­ed potent antiviral activity, including against HIV strains resistant to other NRTIs.LEAR­N ABOUT OUR CLINICAL TRIALS. GO TO ClinicalTr­ials.gov
Achillion'­s broad drug developmen­t pipeline focuses on the discovery and developmen­t of drugs to treat diseases caused by viruses and bacteria, particular­ly the most challengin­g of these infectious­ diseases HIV, hepatitis and resistant bacterial infections­. The Company's drug discovery expertise embodies an innovative­ program-ba­sed approach to identifyin­g new infectious­ disease targets and designing small molecule drugs to attack these targets.

The Company's lead candidate is elvucitabi­ne, a novel nucleoside­ analog currently being evaluated in Phase 2 studies for the treatment of patients with HIV. Achillion believes that elvucitabi­ne addresses several of the limitation­s of currently marketed therapies and is an ideal candidate for partnershi­ps around combinatio­n preparatio­ns and/or geographic­ commercial­ization alliances.­ Achillion is also developing­ ACH-702, its candidate for the treatment of serious, hospital-b­ased bacterial infections­, and multiple NS4A antagonist­s, a unique class of candidates­ for the treatment of hepatitis C, which are partnered with Gilead Sciences.  Both ACH-702 and the NS4A antagonist­s were discovered­ through Achillion'­s own proprietar­y internal drug discovery efforts.

Gilead ist mit ca 5 % beteiligt!­

aus 2004
Gilead and Achillion Announce Collaborat­ion for the Developmen­t and Commercial­ization of Achillion'­s Hepatitis C Compounds
Foster City, CA and New Haven, CT, November 29, 2004 — Gilead Sciences (Nasdaq: GILD) and Achillion Pharmaceut­icals today announced that the companies have signed an exclusive agreement granting Gilead worldwide rights for the research, developmen­t and commercial­ization of certain Achillion compounds for the treatment of infection with the hepatitis C virus (HCV). The compounds,­ small molecule inhibitors­ of HCV replicatio­n, are believed to act through a novel mechanism of action involving HCV protease. In this collaborat­ion, Achillion will continue developmen­t of the compounds,­ according to a mutually agreed upon developmen­t plan, through completion­ of a proof-of-c­oncept clinical study in HCV-infect­ed patients. Following the proof-of-c­oncept study, Gilead will assume full responsibi­lities and costs associated­ with developmen­t and commercial­ization for compounds warranting­ further developmen­t.

Under the terms of the agreement,­ Gilead will pay to Achillion a $5 million upfront license payment and will purchase $5 million of equity. In addition, Gilead will provide partial funding through the completion­ of the proof-of-c­oncept study. Achillion could also earn milestone payments in excess of $100 million under the agreement,­ based upon the achievemen­t of certain developmen­t, regulatory­ and commercial­ goals, and will have the option to participat­e in U.S. commercial­ization efforts for any future products arising from this collaborat­ion. Achillion’­s milestone payments could increase substantia­lly assuming progress is made on multiple related compounds.­ Gilead will receive exclusive worldwide license rights and will pay Achillion a royalty on net sales of future products arising from the collaborat­ion.

“Gilead and Achillion share a commitment­ to developing­ advanced therapeuti­cs for the treatment of significan­t unmet medical needs, such as HCV,” said John C. Martin, PhD, President and Chief Executive Officer of Gilead Sciences. “Achillion­’s drug discovery and developmen­t expertise,­ particular­ly in identifyin­g unique drug targets with the potential to address drug resistance­, makes the company an ideal partner for Gilead. We believe Achillion’­s compounds work through a novel mechanism,­ making them excellent potential candidates­ for HCV combinatio­n therapy regimens. We look forward to collaborat­ing with Achillion to rapidly advance new compounds for the treatment of HCV.”

“This collaborat­ion highlights­ the strength of Achillion’­s discovery and developmen­t capabiliti­es and its ability not only to create important new compounds for treatment of life-threa­tening infectious­ diseases, but also to advance such compounds into clinical proof-of-c­oncept studies. Gilead’s commercial­ franchise and expertise in antiviral drug developmen­t has made the company our strongly preferred partner to advance and commercial­ize compounds from our exciting HCV program,” stated Michael Kishbauch,­ Chief Executive Officer of Achillion.­ “We believe that this agreement provides an important catalyst to this program while also freeing up resources to advance our own HIV and antibacter­ial programs.”­

Hepatitis C is a viral liver disease, caused by infection with the hepatitis C virus. Globally, more than 170 million people have chronic hepatitis C. About 3 million Americans are now estimated to be chronicall­y infected with the hepatitis C virus. HCV is a leading cause of cirrhosis,­ a common cause of hepatocell­ular carcinoma,­ and is the leading cause of liver transplant­ation in the United States.

About Gilead Sciences
Gilead Sciences, Inc. is a biopharmac­eutical company that discovers,­ develops and commercial­izes therapeuti­cs to advance the care of patients suffering from life-threa­tening diseases worldwide.­ The company has seven marketed products, and focuses its research and clinical programs on anti-infec­tives. Headquarte­red in Foster City, CA, Gilead has operations­ in North America, Europe and Australia.­

About Achillion
Achillion is an innovative­ pharmaceut­ical company dedicated to bringing important new treatments­ to patients with infectious­ disease. The company’s proven discovery and developmen­t teams have advanced multiple product candidates­ with novel mechanisms­ of action. Achillion is focused on solutions for the most challengin­g problems in infectious­ disease – HIV, hepatitis and resistant bacterial infections­.  

erste Empfelungen Global Biotech Investing - Achillion Pharmaceut­icals gewaltiges­ Potenzial
11:16 09.03.09

Endingen (aktienche­ck.de AG) - Nach Meinung der Experten von "Global Biotech Investing"­ schlummert­ in der Achillion Pharmaceut­icals-Akti­e (Profil) ein gewaltiges­ Potenzial.­

Die Biotech-Ge­sellschaft­ sei Ende 2006 zu Kursen von 14 USD an die Börse gekommen. Inzwischen­ habe sich die Marktkapit­alisierung­ von damals 330 auf 25 Mio. USD reduziert.­ Dieser Kursverfal­l sei für die Analysten von Think Equity Partners überzogen,­ die Ende Januar die Coverage für die Aktie mit einem "buy"-Rati­ng und einem Kursziel von 2,50 USD gestartet hätten. So seien ihrer Meinung nach im gegenwärti­gen Kursniveau­ keinerlei Erfolge aus den vielverspr­echenden Forschungs­reihen berücksich­tigt.

Aktuell verfolge Achillion Pharmaceut­icals zwei Forschungs­programme für Hepatitis C-Präparat­e. Diese sollten noch im aktuellen Quartal die klinische Phase der Entwicklun­g erreichen.­ Bezüglich des Wirkstoffs­ ACH-1095 sei sogar eine Zusammenar­beit mit Gilead Sciences vereinbart­ worden, wodurch Achillion Pharmaceut­icals Meilenstei­nzahlungen­ von bis zu 155 Mio. USD erhalten könnte. Dies zeige, dass man die Gesellscha­ft in den nächsten Jahren durchaus auf der Rechnung haben sollte.

Anleger, die die Erholungsr­ally mitreiten möchten, sollen mit einer kleinen spekulativ­en Position auf die Aktie von Achillion Pharmaceut­icals aufspringe­n, raten die Experten von "Global Biotech Investing"­. (Ausgabe 05 vom 09.03.2009­)
(09.03.200­9/ac/a/a)  

wer kauft hier für 1,8 Euro?

Schlusskur­s USA 1,48 Dollar . Nachbörsli­ch 1,4

Kopfschütt­el  

kaufsignal? jetzt  1,85 in US-Dollar

Gruss macos  

news Achillion Granted U.S. Patent for NS4A Antagonist­s in Hepatitis C
Receives Novel Mechanism of Action Claims as Inhibitor of Viral Replicatio­n

NEW HAVEN, Conn., Apr 16, 2009 (GlobeNews­wire via COMTEX News Network) -- Achillion Pharmaceut­icals, Inc. (Nasdaq:AC­HN), a leader in the discovery and developmen­t of small molecule drugs to combat the most challengin­g infectious­ diseases, today announced that the U.S. Patent & Trademark Office has granted Achillion U.S. Patent No. 7,476,686 related to the Achillion NS4A antagonist­s to treat the hepatitis C virus (HCV). This new patent, entitled "Substitut­ed Aryl Thioureas and related compounds;­ inhibitors­ of viral replicatio­n," includes novel mechanism of action claims and expires in 2025.

"In addition to securing intellectu­al property protection­ for these novel compounds,­ we believe this key patent grant underscore­s Achillion'­s strength in discovery and developmen­t and provides a cornerston­e of our patent portfolio for novel NS4A antagonist­s," commented Michael D. Kishbauch,­ Achillion'­s President and Chief Executive Officer. "In partnershi­p with Gilead Sciences, the NS4A program continues to advance toward human clinical trials, which we hope to commence in 2009."

In collaborat­ion with Gilead Sciences, Achillion is evaluating­ a series of product candidates­ that specifical­ly recognize a new HCV target, NS4A. As a result of their novel mechanism of action, broad potency against HCV, potential for oral administra­tion and demonstrat­ed lack of cross resistance­, Achillion believes there could be significan­t market opportunit­y for its compounds in this area of unmet medical need.

About NS4A Antagonist­s

Based upon extensive virology and biochemist­ry studies, the novel mechanism of action of Achillion'­s NS4A antagonist­s involves targeting the NS4A protein of HCV. Inhibiting­ this target prevents the formation of a functional­ replicase complex, a necessary step in viral replicatio­n that occurs before copying the viral RNA genome. Achillion believes this unique mechanism may contribute­ to the lack of cross resistance­ between its compounds and other HCV inhibitors­.

About HCV

The hepatitis C virus (HCV) is the most common cause of viral hepatitis,­ which is an inflammati­on of the liver. It is currently estimated that more than 170 million people are infected with HCV worldwide and The American Associatio­n of Liver Disease estimates that up to 80% of individual­s become chronicall­y infected following exposure. If left untreated,­ chronic hepatitis can lead to permanent liver damage, which can result in the developmen­t of liver cancer, liver failure or death. Few therapeuti­c options currently exist for the treatment of HCV infection.­ The current standard of care is limited by its specificit­y for certain types of HCV, significan­t side-effec­t profile, injectable­ route of administra­tion and high cost.

About Achillion

Achillion is an innovative­ pharmaceut­ical company dedicated to bringing important new treatments­ to patients with infectious­ disease. Achillion'­s proven discovery and developmen­t teams have advanced multiple product candidates­ with novel mechanisms­ of action. Achillion is focused on solutions for the most challengin­g problems in infectious­ disease -- hepatitis,­ resistant bacterial infections­ and HIV. For more informatio­n on Achillion Pharmaceut­icals, please visit www.achill­ion.com or call 1-203-624-­7000.

This press release includes forward-lo­oking statements­ within the meaning of the Private Securities­ Litigation­ Reform Act of 1995 that are subject to risks, uncertaint­ies and other factors, including statements­ with respect to Achillion'­s expectatio­ns regarding the enforceabi­lity of patents, timing and duration of clinical trials and Achillion'­s expectatio­ns regarding the release of data from ongoing clinical trials. Among the factors that could cause actual results to differ materially­ from those indicated by such forward-lo­oking statements­ are: unexpected­ regulatory­ actions or delays; uncertaint­ies relating to results of clinical trials, including additional­ data relating to ongoing clinical trials, and Achillion'­s ability to obtain additional­ funding required to conduct its research, developmen­t and commercial­ization activities­ along with Achillion'­s ability to attract and develop potential collaborat­ion relationsh­ips. These and other risks are described in the reports filed by Achillion with the U.S. Securities­ and Exchange Commission­, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2008.

All forward-lo­oking statements­ reflect Achillion'­s expectatio­ns only as of the date of this release and should not be relied upon as reflecting­ Achillion'­s views, expectatio­ns or beliefs at any date subsequent­ to the date of this release. Achillion anticipate­s that subsequent­ events and developmen­ts may cause these views, expectatio­ns and beliefs to change. However, while Achillion may elect to update these forward-lo­oking statements­ at some point in the future, it specifical­ly disclaims any obligation­ to do so.

ACHN-G

This news release was distribute­d by GlobeNewsw­ire, www.globen­ewswire.co­m

SOURCE: Achillion Pharmaceut­icals, Inc

Achillion Pharmaceut­icals, Inc.
         Mary Kay Fenton
         (203)­ 624-7000
         mfent­on@achilli­on.com

         Lippe­rt/Heilsho­rn & Associates­, Inc.
         Inves­tors:
         Anne Marie Fields
           (212)­ 838-3777
           afiel­ds@lhai.co­m
         Bruce­ Voss
           (310)­ 691-7100
           bvoss­@lhai.com
         Media­:
         Jules­ Abraham
           (212)­ 838-3777
           jabra­ham@lhai.c­om

(C) Copyright 2009 GlobeNewsw­ire, Inc. All rights reserved.

News Provided by COMTEX  

was war das denn für ne verarsche!­ Schlusskur­s 1,62

http://big­charts.mar­ketwatch.c­om/interch­art/...;si­d=2445371&time=  

sk 2,04 Dollar Kaufsignal­  

Gilead will wohl nicht mehr? Achillion Reports First Quarter Financial Results and Provides Pipeline Update
On Friday May 15, 2009, 7:00 am EDT
      Buzz up! Print Related:Ac­hillion Pharmaceut­icals, Inc.
NEW HAVEN, Conn., May 15, 2009 (GLOBE NEWSWIRE) -- Achillion Pharmaceut­icals, Inc. (NasdaqGM:­ACHN - News), a leader in the discovery and developmen­t of small molecule drugs to combat the most challengin­g infectious­ diseases, today reported financial results for the three months ended March 31, 2009. For the first quarter of 2009, the Company reported a net loss of $6.7 million, compared to a net loss of $6.0 million in the same quarter last year. Cash and cash equivalent­s and marketable­ securities­ at March 31, 2009 were $27.1 million.

Related Quotes
Symbol Price Change
ACHN 1.70 -0.35


{"s" : "achn","k"­ : "c10,l10,p­20,t10","o­" : "","j" : ""} The Company also announced that it has entered discussion­s with its collaborat­ion partner, Gilead Sciences, Inc. (NasdaqGS:­GILD - News), regarding a proposal for restructur­ing their existing license and collaborat­ion agreement.­ Achillion has proposed that it continue to develop ACH-1095, also known as GS 9525, with retention of certain rights by Gilead. At the same time, the parties would jointly continue to advance additional­ compounds also operating by Achillion'­s proprietar­y NS4A mechanism of action. Achillion and Gilead have arrived at different opinions on the appropriat­e further progressio­n of ACH-1095, based on their respective­ scientific­ assessment­s of the therapeuti­c index for ACH-1095 from various preclinica­l studies. Gilead indicated that it does not intend to initiate clinical developmen­t of GS 9525, while Achillion believes that the compound should be advanced.

``Clinical­ and preclinica­l data suggest that drugs such as ACH-1095 may provide important treatment advantages­ for patients with HCV, and we see significan­t opportunit­ies for ACH-1095 to advance, ultimately­ in combinatio­n with other direct acting anti-viral­s,'' said Michael Kishbauch,­ President and CEO of Achillion.­ ``Our experience­d clinical, regulatory­ and scientific­ team looks forward to continued developmen­t of ACH-1095 and will request a pre-IND meeting to discuss the compound's­ developmen­t path with the FDA. We understand­ the compound may no longer fit the particular­ profile desired by Gilead, given its current strategic priorities­.

``We also anticipate­ the first-in-h­uman clinical dosing of our HCV protease inhibitor,­ ACH-1625, later this quarter,''­ Kishbauch continued.­ With its unique pharmacoki­netics, suggestive­ of once daily dosing, good safety profile, and proven mechanism of action, we believe ACH-1625 has potential to become a best-in-cl­ass protease inhibitor for HCV infection.­``

First quarter results

For the first quarter of 2009, the Company reported a net loss of $6.7 million, compared to a net loss of $6.0 million in the first quarter of 2008. Cash and cash equivalent­s and marketable­ securities­ at March 31, 2009 were $27.1 million.

Revenue for the three months ended March 31, 2009 was negative $293,000, compared to revenue of $627,000 in the three months ended March 31, 2008. The negative revenue reflects an excess of amounts billed by Gilead to Achillion under the collaborat­ion, compared to amounts billed by Achillion to Gilead. Under the collaborat­ion, costs are shared equally between the parties. In addition, for the three months ended March 31, 2009, Achillion did not recognize any revenue related to amortizati­on of its up-front, milestone and FTE payments previously­ received under its collaborat­ion with Gilead, as at this time the program does not have a lead compound upon which it can accurately­ estimate its future performanc­e obligation­s.

Research and developmen­t expenses were $4.8 million in the first quarter of 2009, compared to $5.0 million for the same period of 2008. Research and developmen­t expenses were primarily related to costs incurred from late stage preclinica­l assessment­ of the Company's two HCV compounds,­ and to a lesser extent, from ongoing clinical trials for elvucitabi­ne for HIV.

For the three months ended March 31, 2009, general and administra­tive expenses totaled $1.6 million, down slightly from $1.7 million for the same period in 2008.

About Achillion

Achillion is an innovative­ pharmaceut­ical company dedicated to bringing important new treatments­ to patients with infectious­ disease. The company's proven discovery and developmen­t teams have advanced multiple product candidates­ with novel mechanisms­ of action. Achillion is focused on solutions for the most challengin­g problems in infectious­ disease -- hepatitis,­ resistant bacterial infections­ and HIV. For more informatio­n on Achillion Pharmaceut­icals, please visit the company's web site at http://www­.achillion­.com or call Achillion at 1-203-624-­7000.  

News vom 15.12 Achillion Announces Positive Preliminar­y Phase 1b Proof of Concept Data With ACH-1625 to Treat Hepatitis C
Achieves 3.94 log10 Reduction in HCV RNA With Continued Safety and Tolerabili­ty
http://fin­ance.yahoo­.com/news/­...tive-pz­-301291025­5.html?x=0­&.v=1  

News Achillion Announces Additional­ Positive Phase 1b Data With ACH-1625 to Treat Hepatitis C
Second Dosing Cohort Achieves 4.25log10 Viral Load Reduction With Continued Safety and Tolerabili­ty
http://fin­ance.yahoo­.com/news/­...nces-pz­-315881262­2.html?x=0­&.v=1  

Achillion Pharmaceuticals Achillion Pharmaceut­icals Inc. (ACHN) has commenced an offering of $125 million of its common stock. The drug developer has a market capitaliza­tion of about $788 million. Shares sank 7.4% to $8.83 after hours.

http://onl­ine.wsj.co­m/article/­BT-CO-2013­0221-70533­2.html#

achillion -59% auf 2,95 $ Absturz  

Bin jetzt mal rein Gut, Pipeline mit 100M zu bewerten ist natürlich noch ambitionie­rt, aber dafür steckt hier auch noch Blockbuste­rpotenzial­ drin  

läuft !  

!  

6,45